Parkinson's disease (PD) is a complex, multisymptom, neurodegenerative disease affecting primarily older adults. With progression, many individuals become homebound and removed from coordinated, expert care, resulting in excess morbidity, mortality, and healthcare expenditures in acute care settings and institutions. Home visit care models have achieved the triple aim of improving individual and population health while reducing costs in many frail, communitydwelling geriatric cohorts. This study details a novel, interdisciplinary home visit program specifically designed for individuals with PD and related disorders and their family caregivers built upon best practice principles in the care of multimorbid older adults. At each quarterly home visit, a movement disorders-trained neurologist, social worker, and nurse work in parallel with the individual and caregiver to complete a history, physical, detailed medication reconciliation, psychosocial needs assessment, and home safety assessment. A comprehensive, person-centered plan is agreed upon, referrals to community resources are made, standardized documentation is shared, and follow-up communication is instituted. In the first 2 years, 272 visits were conducted with 85 individuals who represent one of the oldest, most disabled PD populations reported. Satisfaction with and retention in the program were high. This study represents the first translation of the success of interdisciplinary and home-based geriatric care models to a population with a specific neurological disease. Preliminary evidence supports the need for such programs in vulnerable populations. Future studies will prospectively assess person-centered outcomes, the effect of using telemedicine on sustainability, and cost effectiveness.
P
arkinson's disease (PD) is a debilitating, progressive, costly neurodegenerative condition affecting more than 1 million people annually in the United States. 1 As PD progresses, individuals become homebound, losing previous access to care. 2, 3 Symptoms increase in number and severity, quality of life declines, 4 and caregiver strain increases. 5, 6 Simultaneously, there is a surge in emergency department (ED) visits, hospitalizations, and institutionalization, 7, 8 each of which confers excess morbidity and mortality on individuals with PD. [9] [10] [11] Individuals with PD are commonly hospitalized for falls and fractures, aspiration pneumonia, infections, and mental status changes. 9 Individuals with PD treated by neurologists are less likely to sustain and be hospitalized for many of these conditions than those not connected to neurological care. [12] [13] [14] Home-based programs provide high-quality care while reducing healthcare costs in complex elderly populations. [13] [14] [15] Most successful models are interdisciplinary, incorporating nursing and social work care coordination. 12, 14, 15 Home visit programs reduce symptoms and healthcare use and increase the likelihood of dying at home, concordant with the individual's wishes. [16] [17] [18] [19] Numerous modalities of physical, occupational, and speech therapies-which can be delivered in the home-can increase independence in activities of daily living and minimize caregiver burden. [20] [21] [22] [23] Such therapies have never been investigated in individuals with advanced PD. To our knowledge, only 2 home visit programs for PD have been described. 24, 25 One did not describe the individuals served, outcomes achieved, or cost effectiveness, and the other included only 7 individuals. 25 We sought to translate what is known about innovative geriatric care models and guiding principles for highquality management of elderly multimorbid adults 26, 27 into an interdisciplinary home visit program to provide continuity of expert neurological care to homebound individuals with advanced PD and related disorders. The aims of the HVP are to identify homebound 28 individuals at risk of loss to follow-up and deliver comprehensive care to facilitate aging in place. The specific objectives have been to increase access to care by extending teambased medical treatment, psychosocial support, and health education; enhance safety; reduce caregiver strain; and empower individuals and families to achieve the best possible quality of life. The HVP was made possible through a grant from the Edmond J. Safra Philanthropic Foundation, with subsequent support from the Parkinson Foundation.
METHODS Setting

Team Members and Structure of the HVP
The HVP team consists of one movement disorders neurologist, one movement disorders fellow, one nurse, and one social worker, who also serves as program coordinator, each with training in movement disorders and geriatric experience. NYU neurologists refer potential participants, or they are identified by chart review. We identified individuals seen at least once at the Fresco Institute with a diagnosis of PD, PD dementia, dementia with Lewy bodies, or atypical parkinsonism living in the 5 boroughs of New York City-a catchment area of 8.5 million 29 -and meeting Medicare criteria for homebound status as potential participants. Participation required at least 1 high-risk condition for hospitalization or institutionalization in PD (see supplemental information). Although this pilot was intended to be limited to NYU patients, program reach was increased by word of mouth, participant support group discussions, website and electronic newsletter postings, and referrals from foundations. All external referrals required at least 1 evaluation by a movement disorders neurologist at the Fresco Institute for diagnostic confirmation.
Home Visit Activities
The program coordinator confirmed eligibility and telephoned the individual or caregiver to explain the HVP, gauge interest, and schedule the initial visit ( Figure 1) . The team sent a welcome letter, confirming the visit, accompanied by the Unified Parkinson's Disease Rating Scale (UPDRS) for participants' subjective ratings of their motor and nonmotor symptoms and activities of daily living. 30 At the initial visit, the nurse, social worker, and neurologist traveled to the individual's home. Team member tasks are depicted in Figure 1 . After introductions, the team reiterated the objectives and HVP structure. The social worker reviewed the individual's demographic characteristics, living situation, in-home services, and hospital and ED visits in the past year and conducted a psychosocial needs assessment of the individual and caregiver(s), if present. The social worker determined whether the individual had an accessible primary care provider (PCP), because the aim of the HVP neurologist was to complement, rather than supplant, the role of the PCP. The social worker discussed goals of care, identifying and clarifying advance directives to ensure that all parties understood the individual's wishes. If an informal, unpaid caregiver was present, the social worker administered the Multidimensional Caregiver Strain Index. 31 While the social worker was speaking with the caregiver, the nurse gathered vital signs, including orthostatic blood pressure because of its prevalence and associated falls. 32 With the neurologist present, the nurse reviewed the UPDRS I & II, specifically, tremor; falls; freezing of gait; dysphagia; and ability to dress, toilet, and ambulate independently. The nurse completed a detailed medication reconciliation, reviewing the individual's strategy for managing multiple medications (e.g., pillbox, timers) and each prescription, over-the-counter medication, or supplement, comparing the actual regimen to that listed at the most recent outpatient encounter. The nurse then conducted a home safety assessment to identify potential fall risks and safety hazards, with particular attention to bathrooms, kitchen safety, clutter, and uneven floors.
Simultaneously, the neurologist reviewed new symptoms or concerns, including unintentional weight loss, constipation, and other advanced PD symptoms not represented on the UPDRS. The neurologist inquired about benefits, side effects, and timing of the therapeutic regimen. Next, she conducted a thorough physical examination, including the UPDRS motor scale.
After completion of these tasks, the team regrouped in the individual's presence to formulate a comprehensive assessment and plan, including medication changes, dietary recommendations, fall precautions, home safety recommendations, and referral provision. Referrals ranged from in-home physical, occupational, speech, and swallowing therapies to supportive counseling and friendly visitor services and home-based primary care referrals for qualifying individuals in eligible areas. For individuals without access to other care, the neurologist managed pressing medical issues based on team expertise. In-home assessment included identifying and managing lifethreatening medical and psychosocial problems with activation of emergency medical services.
All recommendations were negotiated with the individual, written in plain language, and orally reviewed with teach-back, and remaining concerns were solicited. Participants were given a copy of the recommendations, updated medication list, details about referrals being made, and team contact information and provided with and educated about a Parkinson Foundation Aware in Care Kit, 33 designed to mitigate excess morbidity and mortality in the inpatient setting through patient empowerment and provider education.
After each visit, the HVP neurologist reviewed all recommendations with the referring neurologist to establish consensus and ordered prescriptions and referrals. Team members documented their portions of the visit using program-specific electronic medical record templates. The neurologist created a comprehensive, interdisciplinary note shared with all of the individual's healthcare providers, including any identified PCP. Two weeks after each visit, the nurse or social worker conducted a follow-up telephone call with the individual or caregiver, addressing any remaining needs. Finally, the entire team convened weekly to review recent patients, identify outstanding concerns, and strategize about process improvement.
Subsequent visits were scheduled every 4 months, with reminders sent 1 month and 48 hours before each visit. At each visit, the team obtained the number of hospital and ED visits since the prior home visit, and use within our institution was confirmed by chart review. Some HVP participants continued to see their referring specialist in the outpatient clinic, because many had longstanding relationships. For those maintaining in-clinic visits, home and clinic visits were offset by 2 months to avoid service duplication.
After 4 visits, participants and caregivers were asked to complete and mail back the Client Satisfaction Inventory Short Form (CSI-SF) after the HVP team left. 34 Participants were instructed to provide honest, anonymous feedback regarding satisfaction with the HVP. Participants could leave the HVP at any time or be discontinued if care needs were met, if they no longer met homebound criteria, or if they moved out of the catchment area.
Data Collection and Analysis
We conducted a retrospective chart review using the institutional electronic medical record for all HVP visits performed through July 2016. Data were collected and managed using REDCap secure, web-based tools hosted at NYU 35 and exported to Stata version 14 for analyses. The NYU institutional review board approved this study.
At Visit 1, we collected information on demographic and PD-relevant variables, including diagnosis and disease duration. At each visit, we assessed Hoehn and Yahr disease stage, with 1 5 mild, unilateral symptoms, 2 5 mild, bilateral symptoms, 3 5 bilateral symptoms with balance impairment, 4 5 severe symptoms but able to ambulate, and 5 5 wheelchair-or bedbound state. 36 To determine program effort, feasibility, and quality, we analyzed the number of people reached, visit numbers and duration, time spent traveling to and from visits, and data on protocol adherence and therapeutic recommendations at each visit. We administered the CSI-SF beginning in 2015to participants completing 4 or more visits. We collected data on duration of follow-up in the HVP in personmonths and percentage of participants reporting any ED or hospital visit in the 12 months preceding HVP entry and during follow-up.
RESULTS
Participant Characteristics
Between February 2014 and July 2016, the HVP team conducted 272 visits with 85 unique individuals. The baseline characteristics of the cohort are shown in Table 1 
Feasibility
Participants received a median of 3 visits (range 1-7) during the study period, with 28% seen only once. At the time of data censoring, 26 participants had withdrawn from the program; 19 died, 2 moved out of the area, 1 left the NYU practice, and the HVP team deemed 4 well enough to no longer require visits. Of 59 within the catchment area and with continued need, 58 opted to continue visits (98.3% acceptability). Of those with at least 2 home visits, 70.5% saw their outpatient neurologist at least one more time (median 1, IQR 0-4), although 63.9% also had at least 1 missed or cancelled appointment (median 1, IQR 0-3).
Median travel time for visits was 30 minutes (IQR 20-40 minutes), and median visit duration was 70 minutes (IQR 60-90 minutes). A completed visit was defined as one in which the following were documented: vital signs, history, examination including UPDRS, medication reconciliation, psychosocial evaluation of the individuals, and interdisciplinary care plan. As defined, 83.5% of all visits were completed. Home safety assessments were completed at 98.2% of all visits, and advance directives were addressed at least once with 89.4% of patients (62.4% of all first visits).
Medication changes were recommended at 41.9% of all visits. Nonpharmacological treatment changes were recommended at 45.2%, including specific recommendations for dietary or behavioral changes, fall precautions, or assistive devices. Moreover, therapy or service referrals were made at 92.7% of all visits (Table 2) .
Satisfaction
Almost half (48.8%) of participants and 31.4% of caregivers completed the CSI-SF. The 7-item scale is scored from 0 to 100, with 100 being perfect satisfaction. Median satisfaction score was 96.3 (IQR 88.9-100) for participants and 98.1 (IQR 94.4-100) for caregivers. 
DISCUSSION
For the first 2 years of our interdisciplinary HVP for PD and related disorders, in more than 270 visits, our team provided coordinated, in-home care to 85 individuals, the majority of whom had severe disease or were bed or wheelchair bound at program entry. Thirteen percent lacked any form of caregiver, limiting access to outpatient appointments. Thus, we believe we served a unique population whose advanced disease typically causes estrangement from care.
37
Of those eligible to continue participation, only one chose to discontinue further visits, and satisfaction was extremely high, highlighting HVP feasibility and subjective value.
High retention and satisfaction may have been due to perceived lack of healthcare alternatives, although we believe that the interdisciplinary structure, well-defined workflows and communication protocols, and connection to community and in-home resources yielded a thorough, high-quality experience 27 that included more effective medication reconciliation than was probably possible during an office visit, with an emphasis on treatment feasibility, reduction of polypharmacy, and detection of medication errors. At least one medication change was made in 41.9% of all visits; to our knowledge, the rate of outpatient PD medication changes has not otherwise been reported. We suspect that our rates may be higher than in most outpatient settings because of availability of time for comprehensive review and screening for inappropriate medications, nonadherence, and previously untreated nonmotor symptoms and comorbidities. Findings from a single-center, pharmacist-led study of a structured medication review and intervention for individuals with PD, in which 95 medication intervention opportunities were identified in 90 individuals, support this hypothesis. 38 Our psychosocial evaluation focused on unmet needs and corresponding solutions. Furthermore, in-home assessments illuminated potential undetected comorbidities and safety hazards to address proactively before falls, injuries, ED visits, or hospitalizations ensued. By fostering continuity of care through enhanced counseling and education, follow-up calls, and subsequent visits, fragmentation of care was diminished, probably reducing caregiver strain and resulting institutionalization for these high-risk individuals. 39 Our comprehensive, interdisciplinary plan was grounded in attention to participant preferences, comorbidities, prognoses, and shared decision-making, with the provision of evidence-based recommendations when possible, 26 which the high percentage of participants (89.4%) with whom advance care planning was addressed at some point during their HVP tenure highlighted. The prevalence of such discussions in neurological populations is generally unknown. One study in palliative-stage PD demonstrated that many individuals were unaware of whether they had an advance directive. 37 In a broader study of New York City's elderly population, only 32% of participants reported any advance care planning. 40 More recently, for 2,155 individuals with Stage IV cancer, oncologists documented goals-of-care discussions with only 27% despite a median of 6 visits. 41 Identifying best practices for goals-ofcare discussions in the PD population requires further study. Finally, we detected a small decrease in hospital and ED visits before and during HVP enrollment, suggesting a potentially beneficial improvement in healthcare use in this high-cost population.
Limitations
Despite demonstrating HVP as a feasible model of care, certain factors limit generalizability. New York City's resources helped minimize travel time and costs, both of which may be greater elsewhere. Similarly, nonurban areas may have a relative lack of general neurologists, movement disorders specialists, and community resources for homebound individuals, 42, 43 suggesting a role for telemedicine to achieve expansion. 43, 44 Our selection of outcome measures is another potential limitation. Selecting optimal measures is challenging, particularly in a neurodegenerative condition in which many symptoms inevitably worsen over time and multimorbidity is common. Evaluation data were collected through chart review, and we lack data on fall rates, hospital days, and costs. In ongoing work, we are studying the UPDRS decline in these individuals with advanced PD, along with fall rates, hospital days, ED visits, percentage dying at home with hospice, and healthcare costs. Also, our response rate to the satisfaction instrument was low, which might reflect social desirability bias.
Finally, to be applicable for broader implementation and dissemination, data on sustainability and cost effectiveness will be necessary. As with many intensive programs in complex elderly populations, sustainability will be predicated on a reduction of high-cost usage, such as ED visits, hospital days, and nursing home placement, which can only be addressed using a larger sample size, a longer time horizon, and comparator data. 
Implications
With the increasing burden of chronic disease, the need for a sustainable home-based care model remains of utmost importance to address the growing needs of our aging population. 45 Programs such as Independence at Home 46 have successfully served elderly adults with chronic conditions other than PD and have highlighted the need to shift the paradigm of how we deliver quality, effective, person-centered care to our most vulnerable populations. [47] [48] [49] Despite the value of home-based care, and the estimated 2 to 4 million homebound individuals in the United States, there is a shortage of PCPs for these individuals. 50, 51 In our 85 participants, our team uncovered many reporting lack of access to primary care, yet we were successful in referring only 5 individuals to homebased primary care because of long wait lists and limited catchment areas. In our view, this PD-focused HVP differs from a traditional home-based practice in the same way that an outpatient movement disorders center differs from a PCP's office; namely, the HVP's focus is the individual's neurological condition. Although our program was never intended to replace the critical primary care connection, our experience highlighted this significant unmet need.
The challenges of travel for specialty care access have raised interest in telemedicine for delivering care specifically for individuals with PD with difficulty reaching a trained specialist. In ongoing work funded by the National Institutes of Health, we will be comparing the HVP model with a telemedicine component with usual care for individuals with advanced PD.
CONCLUSION
By fostering continuity of expert, interdisciplinary care for advanced PD through a home visit model, we have demonstrated the ability not only to reach this vulnerable population, but also to provide meaningful services and care to those most in need of them.
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